Compare Neurocrine Biosciences Inc (NBIX) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.

The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.

Advanced Drainage Systems (WMS) trades at $126.08, down 3.07% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding expectations. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. The company maintains strong profitability metrics, including a 24.9% ROE, and recently announced a quarterly dividend. Analyst consensus is mixed with a $188.70 price target, while institutional activity shows both new acquisitions and reductions in holdings.

WMS presents a balanced outlook with solid fundamentals and recent earnings beats offset by near-term technical weakness. Investment opportunities include sustained revenue growth and margin expansion from operational efficiencies. Key risks involve competitive pressures in the construction sector and potential volatility from macroeconomic factors. The stock's current valuation at a P/E of 21.48 offers a reasonable entry point relative to growth prospects, but investors should monitor cash flow trends given the projected net cash outflow in 2026.